{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-036263","form_type":"8-K","ticker":"PTCT","cik":"0001070081","company_name":"PTC THERAPEUTICS, INC.","filed_at":"2023-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.771731+00:00","generated_at":"2026-06-17T16:10:15.612968+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"PTC Therapeutics appoints Matthew Klein as CEO; founder Stuart Peltz retires","bullets":["Stuart Peltz retires after 25 years as CEO; Matthew Klein appointed CEO and President, effective March 22, 2023.","Peltz will serve as Senior Advisor & join Scientific Advisory Board; consulting fee of $600k for first 12 months, then $400k.","Klein had been COO since Jan 2022; previously Global Head of Gene & Mitochondrial Therapies and Chief Development Officer.","Peltz receives prorated 2023 annual bonus equal to 25% of his 2022 bonus; unvested equity continues vesting during consulting period.","PTC's broad pipeline includes five registration-directed trials; Klein led EMA approval of Upstaza gene therapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-036263","json":"https://secwatch.observer/filing/0001104659-23-036263.json","markdown":"https://secwatch.observer/filing/0001104659-23-036263.md","text":"https://secwatch.observer/filing/0001104659-23-036263.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070081/000110465923036263/0001104659-23-036263-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070081/000110465923036263/tm2310367d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T16:10:15.612968+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"141a07739c","claim":"Stuart W. Peltz retired as Chief Executive Officer at PTC THERAPEUTICS, INC..","evidence_excerpt":"Dr. Stuart W. Peltz, who provided the Board with notice on March 22, 2023 of his decision to retire as Chief Executive Officer and as a member of the Board, in each case, effective as of March 22, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1070081/000110465923036263/0001104659-23-036263-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"f5f22247b0","claim":"Matthew B. Klein was appointed as Chief Executive Officer and President at PTC THERAPEUTICS, INC..","evidence_excerpt":"the Board of Directors (the “Board”) of PTC Therapeutics, Inc. (the “Company”) appointed Dr. Matthew B. Klein, age 51, as Chief Executive Officer and President and a member of the Board, effective as of March 22, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1070081/000110465923036263/0001104659-23-036263-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer and President"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}